Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group S.p.A. (NYSE: STVN) has filed Amendment No. 1 (Form 20-F/A) to its 2021 Annual Report with the SEC to add the Interactive Data File and provide additional information. This was filed on
Shareholders can access the Form 20-F/A at www.stevanatogroup.com. A printed copy is available upon request.
Stevanato Group (NYSE: STVN) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, presenting virtually on March 22, 2022 at 9:00 a.m. EDT. A live audio webcast will be accessible on their website, with a replay available for 90 days post-event. The press release includes forward-looking statements regarding the company’s business strategies and recognizes the uncertainty in predicting future events. Founded in 1949, Stevanato Group specializes in drug containment and delivery solutions for the pharmaceutical and biotechnology sectors.
Stevanato Group (NYSE: STVN) has announced the acquisition of a new facility in Zhangjiagang, China, marking a strategic expansion phase. This 32,000 square meter facility will support the production of pre-sterilized EZ-fill® syringes and vials, meeting the growing demand in the biotech sector. Construction is set to begin in spring 2022, with production expected to start in 2023 and operational lines by early 2024. The expansion aims to streamline the drug development supply chain, with the potential to double current production capabilities by the end of 2024.
Stevanato Group (NYSE: STVN) reported a 12.5% increase in fourth quarter revenue to €232.6 million, with diluted EPS at €0.17 and adjusted EPS at €0.13. Full year revenue rose by 27.5% to €843.9 million. The company announced guidance for 2022, expecting revenue between €935 million to €945 million, with adjusted EPS projected at €0.49 to €0.51. Key drivers include strong performance in high-value solutions and demand for Covid-related products. The backlog also increased to €880 million, indicating robust future growth.
Stevanato Group (NYSE: STVN) has secured approximately
Stevanato Group (NYSE: STVN) announced it will release its financial results for Q4 and full year 2021 on March 8, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET on the same day, during which management will discuss the results and refer to a slide presentation available on their Investor Relations website. Participants can preregister or access the live call via provided links. An online archive of the call will be accessible after the live session until March 22, 2022.
Stevanato Group has appointed Riccardo Butta as President of the Americas, reinforcing its commitment to growth in the region. Butta brings over 30 years of management experience, including 20 years at Flex Ltd., where he oversaw the global commercial operations of Flex Health Solutions. This strategic move aims to enhance market penetration and customer proximity amid growing regional demand. CEO Franco Moro expressed confidence in Butta's capabilities to advance the company’s strategic priorities in this critical area.
Stevanato Group has extended its licensing agreement with Haselmeier for the Axis-D™ pen injector technology, broadening its offerings beyond diabetes to include obesity, cardiovascular disease, gastrointestinal disorders, pain management, and more. This strategic move enhances Stevanato's product portfolio and positions it to meet the increasing demand for drug delivery systems. The Alina® platform is designed for a variety of therapeutic regimens, ultimately benefiting patients and pharmaceutical companies during the drug development process.
Stevanato Group (NYSE: STVN) announced the construction of a new 6,750 square meter corporate headquarters in
Stevanato Group (NYSE: STVN) reported a 37% revenue increase to €214.5 million in Q3 2021, alongside a net profit of €18.6 million and diluted EPS of €0.07. Adjusted net profit rose 39% to €26.4 million, with adjusted diluted EPS at €0.10. The backlog also grew to €834 million. A discretionary bonus of €6.7 million affected net profits, but the company remains optimistic, raising its revenue guidance for the year and projecting adjusted diluted EPS between €0.45 and €0.47.